National Healthcare Group Eye Institute, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
BMC Ophthalmol. 2013 Aug 8;13(1):41. doi: 10.1186/1471-2415-13-41.
Investigations used to aid diagnosis and prognosticate outcomes in ocular inflammatory disorders are based on techniques that have evolved over the last two centuries have dramatically evolved with the advances in molecular biological and imaging technology. Our improved understanding of basic biological processes of infective drives of innate immunity bridging the engagement of adaptive immunity have formed techniques to tailor and develop assays, and deliver targeted treatment options. Diagnostic techniques are paramount to distinguish infective from non-infective intraocular inflammatory disease, particularly in atypical cases. The advances have enabled our ability to multiplex assay small amount of specimen quantities of intraocular samples including aqueous, vitreous or small tissue samples. Nevertheless to achieve diagnosis, techniques often require a range of assays from traditional hypersensitivity reactions and microbe specific immunoglobulin analysis to modern molecular techniques and cytokine analysis. Such approaches capitalise on the advantages of each technique, thereby improving the sensitivity and specificity of diagnoses. This review article highlights the development of laboratory diagnostic techniques for intraocular inflammatory disorders now readily available to assist in accurate identification of infective agents and appropriation of appropriate therapies as well as formulating patient stratification alongside clinical diagnoses into disease groups for clinical trials.
用于辅助眼部炎症性疾病诊断和预后的研究方法基于过去两个世纪以来不断发展的技术,随着分子生物学和成像技术的进步,这些技术已经发生了巨大的变化。我们对感染性和先天免疫的基本生物学过程以及适应性免疫的参与的理解的提高,已经形成了定制和开发检测方法以及提供靶向治疗选择的技术。诊断技术对于区分感染性和非感染性眼内炎症性疾病至关重要,尤其是在不典型病例中。这些进展使我们能够对包括房水、玻璃体或小组织样本在内的眼内样本进行少量样本的多重检测。然而,为了进行诊断,技术通常需要从传统的过敏反应和微生物特异性免疫球蛋白分析到现代分子技术和细胞因子分析等一系列检测方法。这些方法利用了每种技术的优势,从而提高了诊断的敏感性和特异性。本文综述了眼内炎症性疾病的实验室诊断技术的发展,这些技术现在可用于辅助准确识别感染因子并采用适当的治疗方法,以及与临床诊断一起将患者分层为临床试验中的疾病组。